At what enterprise value was VISTA VISION acquired in 2024?

During the acquisition of VISTA VISION by ARDIAN in 2024, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 100M - 350M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of VISTA VISION when it was acquired by ARDIAN?

The estimated EV/EBITDA multiple for VISTA VISION is in the range of Above 20x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was VISTA VISION acquired by ARDIAN?

VISTA VISION was acquired by ARDIAN in 2024.

What was the revenue of VISTA VISION at the time of the deal?

The revenue of VISTA VISION at the time of the deal is estimated to be in the range of 50M - 100M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of VISTA VISION during the acquisition?

VISTA VISION's EBITDA is estimated to be in the range of 5M - 25M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the VISTA VISION acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the VISTA VISION deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.ardian.com/fr/actualites-perspectives/communiques-de-presse/ardian-acquiert-une-participation-majoritaire-dans

← DATABASE

Home Database Healthcare & PharmaVISTA VISION

10/2024

VISTA VISION acquired by ARDIAN

ITALY Health Providers / Outpatient Care / Ophthalmology EV 100M - 350M EUR

Context

Ardian Expansion acquired a majority stake in Vista Vision from its founders and Credem Private Equity. The transaction marks a new strategic phase for the group, following a period of rapid expansion where revenues tripled under Credem's tenure. The founders reinvested significantly alongside Ardian to remain minority shareholders and lead the next growth cycle. The strategic roadmap focuses on aggressive buy-and-build activity in the highly fragmented Italian market—with eight acquisitions already in the pipeline—and international expansion across Romania and other European countries. The deal highlights the "social infrastructure" appeal of specialized healthcare services driven by increasing demand for elective surgeries and advanced ophthalmic care.

VISTA VISION, which reported an EBITDA margin of in 2023, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 2003, Vista Vision is a leading Italian provider of high-quality ophthalmic and refractive surgery services. The network specializes in laser correction (myopia) and cataract surgery, operating 12 clinics in Italy and 5 in Romania. The company functions as a premium platform for top ophthalmologists, providing them with state-of-the-art operating rooms, cutting-edge medical equipment, and highly qualified medical staff.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2023

2022

Similar deals in Health Providers

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
11/2024	GROUPE IMAGERIE CARDINET	RADIOLOGIE PARIS OUEST	FRANCE	Radiology
11/2024	WELLTOWER	CARE UK	UNITED KINGDOM	Nursing Homes
10/2024	MONTEFIORE INVESTMENT	DEMENEGO	ITALY	Ophthalmology
10/2024	QUALIUM	IMPC (IMAGERIE MEDICALE PARIS CENTRE)	FRANCE	Radiology
08/2024	ORLANDO HEALTH	BROOKWOOD BAPTIST HEALTH SERVICES	UNITED STATES	Clinics / Hospitals
06/2024	L-GAM / CAPZA / IDIA CAPITAL INVESTISSEMENT	PSV GROUP	FRANCE	Radiology
06/2024	INTEGRAL DIAGNOSTICS LIMITED	CAPITOL HEALTH LIMITED	AUSTRALIA	Radiology
01/2024	ARDIAN / BPIFRANCE / MACSF	APRIUM PHARMACIE	FRANCE	Pharmacy
12/2023	ANDERA PARTNERS	GROUPE IMAGERIE CARDINET	FRANCE	Radiology
12/2023	ESSLING CAPITAL	X-RAY PHOCEA	FRANCE	Radiology

REFERENCES

Valuation range: EV 100M - 350M EUR

Revenue range: 50M - 100M EUR

EBITDA range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of VISTA VISION by ARDIAN are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Acquirer: ardian